Introducing Iron Isomaltoside Injection by PharmAlliance International Labs

Welcome to PharmAlliance International Labs, where we are dedicated to pioneering healthcare solutions that elevate the quality of life for individuals worldwide. Our Iron Isomaltoside Injection marks a significant breakthrough in the treatment of iron deficiency anemia, offering a potent and well-tolerated option for patients requiring iron supplementation. With a steadfast commitment to excellence in pharmaceutical manufacturing and patient care, we strive to set new standards in healthcare innovation and efficacy.

Drug Classification:

Iron Isomaltoside Injection falls under the category of iron supplements. This formulation delivers a highly bioavailable form of iron, ensuring rapid and effective correction of iron deficiency anemia by replenishing depleted iron stores and supporting erythropoiesis.

Formulations:

Iron Isomaltoside Injection:

• • Strength: Each liquid ampule contains 100 mg of Iron (as Iron Isomaltoside).
  • Product Form: Injectable solution for intravenous administration.
  • Packing Specs: Available in packs of 5 liquid ampoules for convenient dosing and storage.

Indications:

Iron Isomaltoside Injection is indicated for the treatment of iron deficiency anemia in adult patients who are intolerant to oral iron preparations or have a clinical need for rapid iron repletion. It is particularly beneficial for individuals with chronic diseases such as inflammatory bowel disease, chronic kidney disease, or heart failure, where oral iron absorption may be impaired or insufficient.

Usage:

This injection should be administered under the supervision of a healthcare professional experienced in managing iron deficiency anemia. It is intended for intravenous use only and should not be administered via other routes. Prior to administration, the liquid ampule should be visually inspected for any signs of contamination.

Dosage:

The recommended dosage of Iron Isomaltoside Injection is determined based on the patient’s iron deficit, hemoglobin levels, and clinical response to treatment. Dosage adjustments may be necessary for patients with severe iron deficiency anemia or underlying medical conditions affecting iron metabolism.

Pharmacokinetics:

Iron Isomaltoside is a stable, water-soluble complex designed to facilitate the controlled release of iron into the bloodstream. Following intravenous administration, it undergoes rapid dissociation, releasing iron ions that bind to transferrin and are transported to the bone marrow for incorporation into hemoglobin.

Pharmacodynamics:

This injection replenishes iron stores and supports erythropoiesis, leading to an increase in hemoglobin levels and resolution of iron deficiency anemia. The controlled release of iron minimizes the risk of adverse effects associated with rapid infusion, ensuring patient safety and tolerability.

Side Effects:

Common side effects may include transient gastrointestinal disturbances, while hypersensitivity reactions, although rare, may occur following intravenous administration. Patients should be closely monitored for signs of allergic reactions during and after infusion.

Trust in the efficacy and safety of Iron Isomaltoside Injection from PharmAlliance International Labs. With our unwavering dedication to quality and patient well-being, we strive to provide pharmaceutical products that significantly improve the lives of individuals affected by iron deficiency anemia. For more information, please visit our website or consult your healthcare provider.